Lucid Diligence Brief: GSK and Syndivia preclinical ADC in mCRPC
Lucid Diligence Brief: GSK and Syndivia preclinical ADC in mCRPC Professional…
Lucid Diligence Brief: Takeda and Innovent global oncology partnership
Lucid Diligence Brief: Takeda and Innovent global oncology partnership…
Lucid Diligence Brief: Ipsen to acquire ImCheck Therapeutics
Lucid Diligence Brief: Ipsen to acquire ImCheck Therapeutics Professional…
Lucid Diligence Brief: Tubulis €308m Series C, NaPi2b ADC TUB-040
Lucid Diligence Brief: Tubulis €308m Series C, NaPi2b ADC TUB-040 Professional…
Oncology Today: ADCs, PD-L1 & FDA Wins (Oct 6–13, 2025)
This week’s oncology highlights include breakthrough therapies such as ADCs…
Lucid Diligence Brief: Shuttle Pharma x Molecule.ai LOI
Lucid Diligence Brief: Shuttle Pharma x Molecule.ai LOI Professional audiences…
Lucid Diligence Brief: Ascenta Capital Fund I, $325M final close
Lucid Diligence Brief: Ascenta Capital Fund I, $325M final close Professional…
Trending in Health Mobile Apps H1 2025
📊 Trending in Health Mobile Apps: Current Trends, Rankings and Insights from H1…
ENDO 2025 Preview: Endocrinology Highlights to Watch
ENDO 2025 at a glance Get ready for ENDO 2025, where Endocrinology…
Cell and Gene Therapy Weekly News - June 5th 2025
This Week in Gene & Cell Therapy: Breakthrough Trials, Fast Track…
Cell and Gene Therapy Weekly News - May 29th 2025
This Week in Gene & Cell Therapy: Clinical Trial Expansions, Rare Disease…
ASGCT 2025 Preview
🔬 ASGCT 2025: Transforming Medicine with Gene Editing, Cell Therapies &……